Clinical trials: Weight Change, Body
Obesity
Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults
The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate…
- Trial name
- NCT00518466
- Testing
- topiramate, phentermine
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight and Obesity, Weight Loss
Study to Evaluate Effects of a Weight Loss Program in Different Formats on Healthy Adults
The objective of this study was to determine changes in body weight and related outcomes achievable over a 16-week period in response to three different commercially available weight loss programs (Nutrisystem) providing…
- Trial name
- NCT03017443
- Testing
- Nutrisystem Turbo 10, Nutrisystem My Way, Nutrisystem DASH
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Nutrisystem, Inc.
Type 2 Diabetes Mellitus, Weight Loss
A Clinical Study of Mass Balance of [14C]HRS-7535
The objective is to evaluate the mass balance of [14C]HRS-7535 in healthy adult Chinese subjects.
- Trial name
- NCT06819488
- Testing
- [14C]HRS-7535
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Acquired Hypogonadotropic Hypogonadism, Obesity
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic…
- Trial name
- NCT02651688
- Testing
- Enclomiphene
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Repros Therapeutics Inc.
Diabetes, Diabetes Mellitus, Type 1
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos
This trial is conducted in Europe. The aim of this trial is to evaluate the effect of Levemir® (insulin detemir) on glycaemic control, weight and incidence of hypoglycaemic events in insulin treated subjects with type 1 or type 2…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542489
- Testing
- insulin detemir, insulin aspart, human soluble insulin
- Where
- Slovakia
- Volunteers
- 480 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes
This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.
- Trial name
- PREDICTIVE™ (NCT00504673)
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- Spain
- Volunteers
- 277 people
- Sponsor
- Novo Nordisk A/S
Obesity
Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
- Trial name
- NCT00297180
- Testing
- GW869682
- Where
- 3 sites in United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Overweight, Weight Loss
Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects
The study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters in overweight subjects during a 12-week consumption period. In addition, tolerability and safety of ProbioSatys™ will be assessed.
- Trial name
- NCT03657186
- Testing
- ProbioSatys™
- Where
- 3 sites in Germany
- Volunteers
- 236 people
- Sponsor
- TargEDys
Diabetes Type 2, Diabetes
Study Evaluating the Metabolic Effects of pulsENDO Therapy in Adults With Type 2 Diabetes
This is a prospective, multicenter, randomized, double-blind, sham-controlled, adaptive study evaluating the pulsENDO system in individuals with type 2 diabetes (T2D) inadequately controlled on non-insulin glucose-lowering…
- Conditions
- Diabetes Type 2, Diabetes, Diabetes (DM), Weight Change
- Trial name
- pulsENDO (NCT07768631)
- Testing
- pulsENDO Therapy
- Volunteers
- 320 people
- Sponsor
- Endogenex, Inc.
Obesity
Safety Evaluation of a Lifestyle Modification Program In.Form 1.1
The study evaluated and compared the safety, tolerance and acceptability of a lifestyle modification program with or without nutritional supplementation in generally healthy overweight subjects with cardiometabolic risk factors.
- Trial name
- NCT03097965
- Testing
- PROGRAM, DIET
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Nature's Sunshine Products, Inc.
Pulmonary Disease, Chronic Obstructive (COPD)
Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices
The purpose of this study was to compare dynamic inspiratory flow rates achieved by a population of Chronic Obstructive Pulmonary Disease (COPD) patients through the Breezhaler®, Ellipta® and Handihaler® dry powder inhaler (DPI)…
- Trial name
- NCT02596009
- Testing
- Breezhaler®, Ellipta®, Handihaler®
- Where
- 5 sites in Argentina
- Volunteers
- 97 people
- Sponsor
- Novartis Pharmaceuticals
Cachexia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of TCMCB07 in Single and Multiple Ascending Doses in Health Subjects
This study will test an experimental drug named TCMCB07 for the treatment of cancer cachexia. Cachexia is a syndrome characterized by weight loss, anorexia, weakness or lack of energy, and anemia.
- Trial name
- NCT05529849
- Testing
- TCMCB07
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Endevica Bio
Overweight and Obesity
Safety and Efficacy of Glucosanol in Reducing Body Weight in Overweight and Obese Subjects
Glucosanol™, the medical device to be investigated contains a proprietary plant extract that is a natural inhibitor of alpha-amylase and can reduce starch digestion.
- Trial name
- NCT01407393
- Testing
- Glucosanol
- Where
- Germany
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Obesity, Overweight
Effect of Orlistat in Body Composition
The purpose of this study is to determine if a 24 week weight loss program with orlistat 60 mg will produce greater changes in body composition compared to placebo.
- Trial name
- NCT00752726
- Testing
- Orlistat
- Where
- 3 sites in United States, Sweden
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Anorexia, Cachexia
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer
- Conditions
- Anorexia, Cachexia, Weight Loss
- Trial name
- NCT00637728
- Testing
- Megestrol acetate concentrated suspension 110 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Par Pharmaceutical, Inc.
Cachexia, Non-Small Cell Lung Cancer
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)
The administration of Anamorelin HCl in patients with Non-Small Cell Lung Cancer-Cachexia (NSCLC-C) is expected to increase appetite, lean body mass, weight gain, and muscle strength.
- Trial name
- NCT01395914
- Testing
- Anamorelin HCl
- Where
- 72 sites in United States, Australia and 15 more
- Volunteers
- 513 people
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Obesity, Behavior, Health
Coached or Non-Coached Weight Loss Intervention
To evaluate the effect of one-on-one coaching in the Noom Healthy Weight Program, a digital behavior change, weight loss intervention, compared to the same program with no coaching, as well as influential factors.
- Conditions
- Obesity, Behavior, Health, Behavior, Eating, Weight Loss
- Trial name
- NCT04645108
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss with 1:1 coaching, Noom Healthy Weight; mobile behavior change program for weight loss
- Where
- United States
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Weight Trajectory
Gamma-linolenic Acid Supplementation Study
Weight regain following weight loss is common. In rodent models of obesity and pilot studies in humans, increasing membrane arachidonic acid content improves fuel partitioning and prevents weight regain.
- Trial name
- GLASS (NCT04481724)
- Testing
- gamma-linolenic acid
- Where
- United States
- Volunteers
- 302 people
- Sponsor
- Virta Health
Epilepsy, Epilepsies, Partial
Prospective Pilot Study on Metabolism and Weight Changes in Topiramate-Treated Epilepsy Patients
The purpose of this study is to assess a possible predictor for weight loss seen in epilepsy patients treated with topiramate.
- Conditions
- Epilepsy, Epilepsies, Partial, Epilepsy, Generalized, Seizures
- Trial name
- NCT00236886
- Testing
- topiramate
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Weight Loss, Appetite Modulation (Focus of Study)
Safety and Efficacy of IQP-AK-102 in Reducing Appetite
The individual ingredients in IQP-AK-102 have been widely used. Backed by data from several studies demonstrating their efficacy, we are conducting this study to look into the efficacy and safety of this novel combination of…
- Trial name
- NCT02041754
- Testing
- IQP-AK-102
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- InQpharm Group